Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Immuno-oncology

An Introduction to Immuno-oncology

Supported by:
International Partner
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

Immuno-oncology is at the heart of Dr Hassan Abushukair’s inspiring journey from Jordan to the USA. A rising star in the field, Hassan combines clinical expertise and bioinformatics to unravel the immune system’s role in cancer, advancing precision medicine. With over 20 publications and prestigious awards, he is paving the way for innovative therapies while championing mentorship and patient-centred research.

Developed by Touch
Coverage from: AACR Highlights

Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around ...

Developed by Touch
Coverage from: AACR Highlights

A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. It was a pleasure to talk with Professor Sandra Demaria (Weill Cornell Medicine, New ...

Developed by Touch
Coverage from: AACR Highlights

A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. We were delighted to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, ...

Developed by Touch
Coverage from: ESMO Highlights

A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. ...

48 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Prof. Caroline Robert, Dr Kluas Busam, Dr Agata Rembielak, Prof. Francesco Bussu, Dr Joël Claveau

In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.

Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART THREE) Question What questions remain unanswered ...

Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART TWO) Questions 1. Could you give us ...

Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART ONE) Questions 1. What has been the ...

Prof Denis Migliorini (Geneva University Hospitals, Geneva, Switzerland) to discuss his presentation at the ESMO Immuno-Oncology Congress 2021 on the challenges of developing CAR-T therapies for brain tumours, and the future of this treatment in clinical practice. Questions 1. What molecules have ...

Prof Denis Migliorini (Geneva University Hospitals, Geneva, Switzerland) to discuss his presentation at the ESMO Immuno-Oncology Congress 2021 on the challenges of developing CAR-T therapies for brain tumours, and the future of this treatment in clinical practice. Questions 1. What are the ...

37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr Ana Arance; Prof. Paolo Ascertio; Dr Allison Betof Warner

Watch leading experts discuss evolving neoadjuvant, adjuvant and metastatic treatment options for patients with melanoma, taking in the latest data presented at the ESMO Congress 2021.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Prof. Axel Hauschild, Dr Emily Ruiz, Prof. Ketty Peris

Watch leading experts discuss evolving treatment options for patients with advanced basal cell carcinoma, and how novel immunotherapeutic approaches within the emerging clinical study landscape may improve patient care.

Coverage from: ASCO GI Highlights

TouchIMMUNOLOGY got the chance to catch up with Hans Prenen (University Hospital Antwerp, Edegem, Belgium) around the potential advantages of non-gene edited allogeneic CAR T cell therapy (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human ...

Coverage from: ASCO GI Highlights

TouchIMMUNOLOGY were delighted to talk to Ken Kato at ASCO’s virtual Gastrointestinal Cancers Symposium 2021 to discuss the potential role of nivolumab in the treatment of gastrointestinal cancers, and how the identification of biomarkers is key to improve clinical response.  ...

Load More...
Close Popup